On April 11, Aeglea BioTherapeutics Inc. (AGLE) stock rallied by nearly 28% in the after-hours trading at a heavy shares traffic of 1.28 million. Thus,
Aeglea BioTherapeutics, Inc. (AGLE) is a clinical-stage biopharmaceutical company engaged in developing human enzyme therapeutics to treat rare metabolic disease patients. One of the lead
At Stocktstelegraph.com, we are committed to helping investors make smart and profitable decisions. Our goal is to make investing easier and more accessible to everyone. We strive to provide the best and most reliable market information, news and analysis to ensure that our readers can make informed decisions.